MetaCap

Genprex (GNPX) vs Kairos Pharma (KAPA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kairos Pharma is the larger company by market cap ($2.0 million vs $1.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GNPX-44.66%KAPA-49.90%
+14%-22%-57%
Oct 7, 20261 yearNov 20, 2026
GNPX-46.69%KAPA-46.21%
+2%-23%-49%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GNPX versus KAPA key metrics
MetricGNPXKAPA
Share price$1.45$0.4359
Market cap$1.94M$2.04M
1-day change-13.17%-4.62%
P/E ratio (TTM)0.01—
EPS (TTM)$98.47$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-16.23M$-5.45M
52-week high$80.96$7.28
52-week low$1.45$0.381
Distance from 52-week high-98.21%-94.01%
Analyst consensus—none
Avg. price target upside—+11141.11%
Average volume168.88K364.25K
Shares outstanding1.33M4.69M
Employees131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Genprex

GNPX stock →

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Kairos Pharma

KAPA stock →

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

GNPX vs KAPA FAQ

Which is bigger, Genprex or Kairos Pharma?

Kairos Pharma (KAPA) is larger, with a market capitalization of $2.04M compared with $1.94M for Genprex (GNPX).

Are Genprex and Kairos Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons